Literature DB >> 12051631

Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma.

Rainer Lehner1, M Scott Lucia, Elke A Jarboe, David Orlicky, A Laurie Shroyer, James A McGregor, Kenneth R Shroyer.   

Abstract

In the current study, the immunohistochemical localization of survivin was correlated with the histologic diagnosis in healthy transitional cell epithelium, transitional cell carcinoma (TCC) in situ, and TCC of the urinary bladder. Forty-five TCCs (grades 1-3, 15 of each), 14 cases of TCC in situ, and II healthy bladder mucosal specimens were selected from archival collections of formalin-fixed bladder tissues. Slides were reacted with an anti-survivin antibody using a conventional immunohistochemical method and then were scored for nuclear and cytoplasmic staining. Statistical analysis of survivin expression was performed to evaluate the correlation of staining pattern with histologic diagnosis and clinical outcome. Nuclear staining for survivin was detected in 26 of 45 TCCs and in 2 of 14 cases of TCC in situ, but was not detected in healthy bladder mucosa. The association of nuclear staining with TCC versus both healthy bladder mucosa and TCC in situ was statistically significant (P < 0.001). Patients with TCC and a nuclear pattern of survivin localization had a greater period of disease-free survival (27.2 months) than was observed in patients with TCC that showed no nuclear staining for survivin (9.9 months); however, the differences were not statistically significant. Nuclear localization of survivin is a marker of TCC but is rarely present in premalignant or benign bladder mucosal specimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051631     DOI: 10.1097/00129039-200206000-00007

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  17 in total

Review 1.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

2.  Nuclear survivin expression predicts poorer prognosis in glioblastoma.

Authors:  Katsuyuki Shirai; Yoshiyuki Suzuki; Kuniyuki Oka; Shin-ei Noda; Hiroyuki Katoh; Yoshihiko Suzuki; Jun Itoh; Hideaki Itoh; Shogo Ishiuchi; Hideyuki Sakurai; Masatoshi Hasegawa; Takashi Nakano
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

3.  Cellular localisation of survivin: impact on the prognosis in colorectal cancer.

Authors:  T Ponnelle; C Chapusot; L Martin; A M Bouvier; S Plenchette; J Faivre; E Solary; F Piard
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-18       Impact factor: 4.553

4.  Nuclear survivin promoted by acetylation is associated with the aggressive phenotype of oral squamous cell carcinoma.

Authors:  Shuli Liu; Lei Shi; Xi Yang; Dongxia Ye; Tong Wang; Cunshan Dong; Wenzheng Guo; Yueling Liao; Hongyong Song; Dongliang Xu; Jingzhou Hu; Zhiyuan Zhang; Jiong Deng
Journal:  Cell Cycle       Date:  2017-04-06       Impact factor: 4.534

5.  Expression of survivin protein in human colorectal carcinogenesis.

Authors:  Lian-Jie Lin; Chang-Qing Zheng; Yu Jin; Ying Ma; Wei-Guo Jiang; Tie Ma
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

Review 6.  Survivin: a promising biomarker for detection and prognosis of bladder cancer.

Authors:  Vitaly Margulis; Yair Lotan; Shahrokh F Shariat
Journal:  World J Urol       Date:  2007-10-26       Impact factor: 4.226

Review 7.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

8.  Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.

Authors:  Min Zhang; Alex Ho; Elizabeth H Hammond; Yoshiyuki Suzuki; R Scott Bermudez; R Jeffrey Lee; Michael Pilepich; William U Shipley; Howard Sandler; Li-Yan Khor; Alan Pollack; Arnab Chakravarti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-30       Impact factor: 7.038

9.  Survivin expression in colorectal carcinomas: correlations with clinicopathological parameters and survival.

Authors:  J G Kalliakmanis; Ch Kouvidou; C Latoufis; G Kouvatseas; D Anagnostakis; G Papatheodoridis; J Koskinas; A Archimandritis
Journal:  Dig Dis Sci       Date:  2009-12-24       Impact factor: 3.199

Review 10.  Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.

Authors:  Ronan J Kelly; Ariel Lopez-Chavez; Deborah Citrin; John E Janik; John C Morris
Journal:  Mol Cancer       Date:  2011-04-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.